entiation and proliferation, and apoptosis, and may also be important in aging and age-related diseases such as cancer (2) and cardiovascular diseases (3, 4) . Organisms with reduced insulin/insulin-like signaling have small body size and increased life span (1) . On the other hand, low IGF-I activity may increase cell apoptosis and reduce tissue proliferation and repair, which is of potential importance in normal human aging; for example, increased apoptosis may produce loss of tissue mass and cellularity and impair tissue regeneration. Organisms with DNA repair defects (e.g. XPF-ERCC1 mouse, and a related human case) have decreased IGF-I and increased IGFBP-1, which may promote both accelerated dysfunction of various organ systems and development of cancer, driven by increased accumulation of somatic mutations (5) .
Because circulating levels and bioactivity of IGF-I decline with aging (6), preventing or reversing age-related decreases in IGF-I is believed to have the potential to delay mortality and increase "health span" (i.e. survival free of disability and disease). Treatments that can produce up to a doubling in IGF-I levels [human GH (hGH) (7) (8) (9) , oral ghrelin mimetic (10) ] have shown no overall benefit in clinical trials, which has not eliminated the use of hGH for "anti-aging" purposes (11) . In fact, whereas some studies, but not others, suggest that low serum IGF-I level is associated with increased mortality (12) (13) (14) (15) (16) (17) , the long-term health outcomes associated with declining endogenous IGF-I levels in older adults have not been assessed in prospective studies. In particular, few if any prior studies of older adults have measured IGF-I and IGFBP levels repeatedly over a long interval of time to see whether changes in the IGF axis predict risk of death.
In an observational study with long-term follow-up, we measured changes in circulating levels of IGF-I and IGFBPs over a period of 9 yr among older men and women. We then examined whether levels and changes in levels of IGF-I, IGFBP-1, and IGFBP-3 were associated with risk of subsequent mortality.
Subjects and Methods

Design overview
The Cardiovascular Health Study (CHS) All Stars Study is a longitudinal cohort study of older adults living in four U.S. communities. Measurements of IGF-I, IGFBP-1, and IGFBP-3 were made using stored blood specimens collected at two time points spanning 9 yr. Levels and changes in levels of IGF-I, IGFBP-1, and IGFBP-3 were examined in relation to subsequent risk of mortality, after adjustment for potential confounders.
Setting and participants
CHS Field Centers enrolled 5888 community-dwelling adults 65 yr and older, including an original cohort of 5201 individuals recruited during 1989 -1990 and an additional cohort of African-American individuals during 1992-1993. Participants were invited to repeated examinations for collection of data and blood specimens. Examinations were conducted annually through 1999. In 2005-2006, as part of the CHS All Stars Study, an additional study examination was conducted on surviving participants, who at that time were all between 77 and 100 yr of age. Follow-up of the study cohort for major health events and deaths through semiannual contacts continues through the present time. All participants provided informed consent, and institutional review board approvals were obtained at all participating institutions.
Study measurements
Physical and cognitive function tests, questionnaires, laboratory panels, and other key covariates were collected at study examinations. The present report uses data from the 1996 -1997 and 2005-2006 examination cycles to define exposures and confounders. Deaths that occurred from the time of the 2005-2006 examination through February 28, 2010 were identified, and cause of death was classified based upon death certificates and medical records.
Laboratory variables
Laboratory measurements were performed using blood collected using standard procedures after an overnight fast and stored at Ϫ70 C. Measurements were performed at the Jewish General Hospital (Montreal, Canada) of IGFBP-1, IGFBP-3, and IGF-I after an extraction step using ELISA methods (Diagnostics Systems Laboratory, Webster, TX) (12) . Assay coefficient of variation was 4 -6% for IGF-I concentration, 3-14% for IGFBP-1 concentration, and 3-5% for IGFBP-3 concentration. Serum creatinine, albumin, C-reactive protein, IL-6, insulin, Cpeptide, and glucose were measured at the CHS Central Laboratory using standard methods (18) .
Clinical variables
Diabetes was defined according to measured fasting glucose levels (Ͼ126 mg/dl) or physician diagnosis with use of diabetes medication. Body mass index was calculated as the measured weight in kilograms divided by the square of measured height in meters. To control for differences in mortality by race, we classified individuals as White or Black/African-American as defined by participant self-report.
Statistical analyses
The main exposure variables of interest were repeated measurements of IGF-I, IGFBP-1, and IGFBP-3 levels at two study examinations approximately 9 yr apart, specifically the 1996 -1997 and 2005-2006 examinations. Changes in IGF-I, IGFBP-1, and IGFBP-3 levels were analyzed both as continuous variables that were scaled to SD of change, as well as in categories defined as decreasing levels (10% or greater decrease), stable levels (10% decrease to 10% increase), or increasing levels (10% or greater increase). With the 2005-2006 visit defined as baseline for mortality follow-up, Cox proportional hazards regression was used to model the association between change in IGF-I or IGFBP level and hazard of death, with censoring at the end of available follow-up in 2010. We also examined whether single measurements of levels of IGF-I and IGFBPs obtained at the baseline (2005-2006) examination were associated with hazard of death. Si-multaneous adjustment for level and change in levels revealed no additional associations beyond those reported here. Analyses were conducted that defined the outcome as death due to cancer (overall, at any anatomic site) with censoring at noncancer death, and as death due to causes other than cancer with censoring at cancer death.
Multivariable models were used to control for potential confounders that may have either obscured or induced an association between IGF-I or IGFBP levels and mortality. Initial models adjusted for age, sex, and race. Subsequent models included additional adjustment for diabetes, body mass index, creatinine, albumin, and C-reactive protein. Interaction terms were used to examine differences by sex in the associations of IGF-I and IGFBP levels with death; these analyses revealed no significant interactions at the P Ͻ 0.05 level. Finally, in sensitivity analyses, we confirmed that findings were similar after exclusion of individuals who had diabetes or congestive heart failure. All statistical analyses were performed using R (R Development Core Team, 2009). P Ͻ 0.05 was defined as the criterion for statistical significance.
The funders had no role in the design, collection, or analysis of study data.
Results
Mean age among 997 participants was 85.2 yr (SD ϭ 3.6 yr) at the 2005-2006 examination, which for this study was defined as baseline for mortality follow-up (Table 1) . At this time, all participants were between 77 and 100 yr of age. The cohort included 528 White women, 107 Black women, 306 White men, and 56 Black men. Deaths subsequent to the 2005-2006 baseline examination were ascertained over a median follow-up of 4.2 yr. During this period, which included 3822 person-years of follow-up, we observed 267 deaths, 39 of which were due to cancer, for a mortality incidence rate of 7.0 deaths per 100 personyears (Table 2) .
Change in circulating IGF levels over 9 yr
At the 1996 -1997 examination, mean (SD) IGF-I levels were 167.0 (61. 4 
Circulating IGF-I levels and mortality
Among 490 individuals with a 10% or greater decrease in IGF-I levels between repeat visits, we observed 145 deaths (cumulative mortality ϭ 29.6%), whereas among 260 individuals whose IGF-I levels remained stable within Ϯ10%, we observed 61 deaths (cumulative mortality ϭ 23.5%) ( Table 2 ). In multivariable adjusted analyses, we found no significant association between risk of overall mortality and change in IGF-I levels between the repeat study visits (Fig. 1) . When analyzed as a continuous variable, change in IGF-I level did not have a significant association with overall mortality. Change in IGF-I level was not associated with either overall cancer mortality or noncancer mortality (Table 3) .
We next examined baseline levels of IGF-I at the 2005-2006 examination as a predictor of subsequent mortality. In models adjusted for age, sex, and race, we found an association between higher IGF-I levels and lower risk of death due to cancer (Table 3) . This association fell short of statistical significance in further multivariable adjusted analyses. For the outcome of overall cancer mortality, after adjustment for age, sex, and race, the hazard ratio for each SD increase in IGF-I levels was 0.68 (95% CI ϭ 0.47, 0.98; P ϭ 0.04). This association was attenuated slightly and was not statistically significant after further adjustment for body mass index, creatinine, albumin, and C-reactive protein (hazard ratio ϭ 0.71; 95% CI ϭ 0.49, 1.03; P ϭ 0.07). Baseline IGF-I levels had no association with noncancer mortality (Table 3) . Although the tabular data considered IGF-I level as a continuous variable, we also For each variable, fewer than 5% of subjects had missing values. Data were missing for 11 subjects for IGF-I and two subjects for IGFBP-3. found no evidence of association between low or high IGF-I level when compared across tertiles. Compared with a middle IGF-I tertile of 120 -171 g/liter, hazard ratios of death were 1.2 (95% CI ϭ 0.89, 1.6) for the lowest IGF-I tertile and 0.97 (95% CI ϭ 0.70, 1.35) for the highest IGF-I tertile.
Circulating IGFBP-1 levels and mortality
Individuals with increasing levels of IGFBP-1 between the repeat visits had significantly elevated risk of overall cancer and noncancer mortality (Table 3 and Fig.1 ). In multivariable-adjusted models, the hazard ratio for overall cancer mortality for each SD increase in IGFBP-1 change was 1.40 (95% CI ϭ 1.10, 1.77; P ϭ 0.01). The hazard ratio for noncancer mortality for each SD increase in IGFBP-1 change was 1.14 (95% CI ϭ 1.02, 1.27; P ϭ 0.02). Those with higher levels of IGFBP-1 at the baseline examination also had significantly increased risk of noncancer mortality (multivariate adjusted hazard ratio for each SD increase in baseline IGFBP-1 ϭ 1.16; 95% CI ϭ 1.04, 1.30; P ϭ 0.01). In contrast to the results for noncancer mortality, overall cancer mortality was not significantly associated with baseline IGFBP-1 levels (P ϭ 0.17).
Circulating IGFBP-3 levels and mortality
Change in IGFBP-3 levels between repeat visits was not associated with overall mortality (Table 3 and Fig.  1 ), cancer mortality (Table 3) , or noncancer mortality (Table 3 ). Higher baseline levels of IGFBP-3 tended to be associated with lower risk of overall cancer mortality, although the association was not statistically significant after adjustment for age, sex, race, body mass index, creatinine, albumin, and C-reactive protein (hazard ratio ϭ 0.72; 95% CI ϭ 0.49, 1.05; P ϭ 0.09) ( Table  3 ). There was no evidence for association between baseline levels of IGFBP-3 and risk of noncancer mortality (Table 3) .
Correlates of change in IGFBP-1 level
As compared with individuals with decreasing IGFBP-1 levels between repeated visits, those with stable or increasing IGFBP-1 levels tended to have lower levels of albumin, IL-6, insulin, and C-peptide (Table 4) . Those with decreasing IGFBP-1 levels also tended to have higher levels of IGF-I (P Ͻ 0.05), and change in IGFBP-1 and change in IGF-I were inversely correlated (r ϭ Ϫ0.29; 95% CI ϭ Ϫ0.34, Ϫ0.23).
Discussion
This study did not confirm the hypothesis that declining IGF-I level is a mortality risk factor. Several prior studies have addressed this question, with conflicting results (12) (13) (14) (15) , although our study is the first, to our knowledge, that measured changes in IGF-I levels over nearly a decade. If the GH/IGF axis is important in longevity and diseases of aging, how can the lack of association between circulating IGF-I and mortality be explained? IGF-I has important paracrine and autocrine activity, as well as endocrine functions, and circulating levels of IGF-I may not accurately reflect IGF-I bioactivity. In addition, total IGF-I levels typically correlate weakly, if at all, with phenotypes that are believed to be influenced by the insulin-like growth system axis. For example, patients with extremely low constitutive levels of circulating IGF-I, such as those with IGFALS gene mutations, can survive to adulthood and have only modest impairments in growth and glucose metabolism (19) . On the other hand, circulating IGF-I levels are high in centenarians with specific IGF1R mutations, and in these individuals IGF-I receptor signaling is defective and height may be reduced (20) . The Zoetermeer study recently reported that low IGF-I bioactivity, as measured by the IGF-I kinase receptor activation assay, predicted increased mortality among older adults, whereas circulating concentrations of total and free IGF-I did not (14) . Measurements of IGF-I bioactivity were unavailable in the present study, which is a limitation. On average, older adults in this study had substantial increases in circulating levels of IGFBP-1 over 9 yr of follow-up. Those with the greatest increases over time in circulating IGFBP-1 level had the highest mortality. This finding was consistent across subgroups of cancer-related deaths and non-cancer-related deaths. By obtaining repeated measurements of IGFBP-1 in an elderly cohort over time, this study further extends the evidence that a high level of IGFBP-1 is a robust mortality risk factor (12, 13) . Notably, the association of increasing IGFBP-1 with mortality was independent of possible confounders and conditions including heart failure, high or low body mass index, inflammation, diabetes mellitus, impaired renal function (creatinine), and malnutrition (albumin), which are common in the elderly and also associated with IGFaxis abnormalities. Hepatic IGFBP-1 production is under strong inverse regulation by insulin and may be stimulated by proinflammatory cytokines (21) . Paradoxically, however, we observed that increasing IGFBP-1 levels, whereas predictive of higher future mortality, was also associated with more favorable levels of IL-6 and glucose metabolism markers (C-peptide and fasting insulin). The finding that high IGFBP-1 and low albumin levels were correlated suggests the hypothesis that covariability between these two analytes may be informative for determining nutritional status in older adults. Therefore, further research is warranted to identify the factors, beyond insulin, that predict, modify, and mediate this phenotype of increasing IGFBP-1 Data are presented as mean Ϯ SD. P values were calculated using F test. Categories were defined as 10% or greater decline in IGFBP-1 levels (ЉdecreasingЉ), 10% or greater increase in IGFBP-1 levels (ЉincreasingЉ), or stable IGFBP-1 defined as levels within Ϯ 10% between repeat visits.
levels. High circulating IGFBP-1 level correlates with low IGF-I bioactivity (14) , and experimental models suggest that IGFBP-1 has IGF-I-inhibitory effects (22) . Rising levels of circulating IGFBP-1 in an older person may therefore reflect a negative regulatory response to dampen anabolic IGF-I-mediated effects. IGFBP-1 may also have IGF-I-independent effects on cell survival (23) . Strengths of this study include its prospective design and long follow-up period. Because levels and changes in IGFs are highly age-dependent, when generalizing these findings it should be noted that the population had a mean age of 85 yr (range, 77 to 100 yr) at the time that we began mortality follow-up. Limitations include an observational study design, which makes it impossible to attribute causality to the association between IGF system proteins and mortality, but which nonetheless permits us to draw conclusions about the ability of circulating biomarkers of IGF status to predict mortality. Mortality risk factors are known to vary by cause of death (24) . Here, we classified events according to cancer and noncancer causes of death, but without specific information on cancer type and with relatively few cancer deaths, which limited our ability to understand cause-specific mortality risks (n ϭ 39).
In conclusion, our study found no evidence that older adults with decreases in IGF-I levels over a period of years have diminished likelihood of long-term survival. A possible increase in overall cancer mortality, but no difference in noncancer mortality, was found comparing individuals with low vs. high IGF-I levels. Although this finding was of borderline statistical significance and is only partially consistent with prior studies (15, 16) , it may be of concern among elderly patients with low IGF-I levels who are treated with hGH because of the drug's potential cancerpromoting potential (25) . We also showed that changes in IGFBP-1 levels with aging are pronounced, and IGFBP-1 may have important IGF-I-dependent or IGF-I-independent mechanisms that influence survival into old age.
